Drug Trial Radar · NCT07400952
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 23, 2025
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Glaukos CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
Conditions
- Keratoconus
Interventions
GLK-221 Ophthalmic SolutionDrug
GLK-221 Ophthalmic Solution administered twice daily to both eyes
Placebo Ophthalmic SolutionDrug
Placebo Ophthalmic Solution administered twice daily to both eyes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in maximum corneal curvatureTime frame: 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Glaukos Clinical Study Site
Westerville, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.